Synaptic Therapy Alzheimer's Research Trial (Start) (H-54151)

The START study is a multicenter randomized, placebo-controlled Phase 2 study designed to evaluate the efficacy and safety of two doses of an investigational oral medication to reduce amyloid plaque accumulation in the brain.  The double-blind phase will last approximately 18 months (72 weeks) and will be followed by an open-label phase in which all participants will receive the study medication.  

To be eligible you must be 50 to 85 years old and have a diagnosis of mild cognitive impairment or mild Alzheimer’s dementia. You must also have a study partner (spouse, other family member, or friend) who can accompany you on visits and provide information about your daily function. You may participate in the trial if you are being treated with other Alzheimer’s medication, including the newly approved monoclonal antibodies, Leqembi and Kisunla (Donanemab).  

Additional information about the trial may be found at clinicaltrials.gov using the clinical trial identification number NCT05531656.